Earnings Feed
Start Free
Home/Filings/4/0001231919-26-000018
4//SEC Filing

RA Capital Healthcare Fund LP 4

Accession 0001231919-26-000018

CIK 0001768446other
View on SEC.govCompany Profile

Filed

Jan 6, 7:00 PM ET

Accepted

Jan 7, 4:55 PM ET

Size

21.5 KB

Accession

0001231919-26-000018

Insider Transaction Report

Form 4
Period: 2026-01-05
Climb Bio, Inc.CLYM
RA CAPITAL MANAGEMENT, L.P.
Director10% Owner
Transactions
  • Purchase

    Common Stock

    2026-01-05$3.50/sh+7,111$24,889→ 3,403,429 total(indirect: See footnotes)
Holdings

  • Common Stock

    (indirect: See footnotes)
    2,479,872

  • Common Stock

    (indirect: See footnotes)
    1,226,497

  • Common Stock

    (indirect: See footnotes)
    483,679

  • Common Stock

    (indirect: See footnotes)
    2,866,375

  • Common Stock

    (indirect: See footnotes)
    841,087
RA Capital Healthcare Fund LP
Director10% Owner
Transactions
  • Purchase

    Common Stock

    2026-01-05$3.50/sh+7,111$24,889→ 3,403,429 total(indirect: See footnotes)
Holdings

  • Common Stock

    (indirect: See footnotes)
    2,479,872

  • Common Stock

    (indirect: See footnotes)
    1,226,497

  • Common Stock

    (indirect: See footnotes)
    483,679

  • Common Stock

    (indirect: See footnotes)
    2,866,375

  • Common Stock

    (indirect: See footnotes)
    841,087
RA Capital Nexus Fund, L.P.
Director
Transactions
  • Purchase

    Common Stock

    2026-01-05$3.50/sh+7,111$24,889→ 3,403,429 total(indirect: See footnotes)
Holdings

  • Common Stock

    (indirect: See footnotes)
    2,479,872

  • Common Stock

    (indirect: See footnotes)
    1,226,497

  • Common Stock

    (indirect: See footnotes)
    483,679

  • Common Stock

    (indirect: See footnotes)
    2,866,375

  • Common Stock

    (indirect: See footnotes)
    841,087
RA Capital Nexus Fund II, L.P.
Director
Transactions
  • Purchase

    Common Stock

    2026-01-05$3.50/sh+7,111$24,889→ 3,403,429 total(indirect: See footnotes)
Holdings

  • Common Stock

    (indirect: See footnotes)
    2,479,872

  • Common Stock

    (indirect: See footnotes)
    1,226,497

  • Common Stock

    (indirect: See footnotes)
    483,679

  • Common Stock

    (indirect: See footnotes)
    2,866,375

  • Common Stock

    (indirect: See footnotes)
    841,087
RA Capital Nexus Fund III, L.P.
Director10% Owner
Transactions
  • Purchase

    Common Stock

    2026-01-05$3.50/sh+7,111$24,889→ 3,403,429 total(indirect: See footnotes)
Holdings

  • Common Stock

    (indirect: See footnotes)
    2,479,872

  • Common Stock

    (indirect: See footnotes)
    1,226,497

  • Common Stock

    (indirect: See footnotes)
    483,679

  • Common Stock

    (indirect: See footnotes)
    2,866,375

  • Common Stock

    (indirect: See footnotes)
    841,087
Kolchinsky Peter
Director10% Owner
Transactions
  • Purchase

    Common Stock

    2026-01-05$3.50/sh+7,111$24,889→ 3,403,429 total(indirect: See footnotes)
Holdings

  • Common Stock

    (indirect: See footnotes)
    2,479,872

  • Common Stock

    (indirect: See footnotes)
    1,226,497

  • Common Stock

    (indirect: See footnotes)
    483,679

  • Common Stock

    (indirect: See footnotes)
    2,866,375

  • Common Stock

    (indirect: See footnotes)
    841,087
Shah Rajeev M.
Director10% Owner
Transactions
  • Purchase

    Common Stock

    2026-01-05$3.50/sh+7,111$24,889→ 3,403,429 total(indirect: See footnotes)
Holdings

  • Common Stock

    (indirect: See footnotes)
    2,479,872

  • Common Stock

    (indirect: See footnotes)
    1,226,497

  • Common Stock

    (indirect: See footnotes)
    483,679

  • Common Stock

    (indirect: See footnotes)
    2,866,375

  • Common Stock

    (indirect: See footnotes)
    841,087
Footnotes (8)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.495 to $3.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • [F2]These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
  • [F3]RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.
  • [F4]These securities are held directly by Sera.
  • [F5]These securities are held directly by the Nexus Fund.
  • [F6]These securities are held directly by the Nexus Fund II.
  • [F7]These securities are held directly by Nexus Fund III.
  • [F8]These securities are held directly by the Account.

Documents

1 file

Issuer

Climb Bio, Inc.

CIK 0001768446

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001315082

Filing Metadata

Form type
4
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 4:55 PM ET
Size
21.5 KB
View on SEC.gov